Which is better for weight loss, semaglutide or tirzepatide?

In clinical trials tirzepatide produced greater average weight loss (about 20–22% at the top dose over ~72 weeks) than semaglutide (about 15% over 68 weeks), because tirzepatide activates two hormone pathways (GIP and GLP-1) versus semaglutide's one. But 'better' depends on your goals, side-effect tolerance, medical history, and budget — many people reach their goals on semaglutide. A physician helps you choose.

The core difference

Semaglutide is a single-agonist that mimics GLP-1. Tirzepatide is a dual-agonist that activates both GLP-1 and GIP receptors, giving a broader effect on appetite and blood sugar. Both are once-weekly injections titrated up slowly to limit side effects.

Choosing between them

Tirzepatide is often more potent on average, while semaglutide is typically the lower-cost starting point and highly effective for most people. Many patients start on semaglutide and switch to tirzepatide to push past a plateau. The decision should be made with a physician based on your health and goals.

Medically reviewed by Dr. Michael Mimlitz, MD (NPI 1508891870), Chief Physician of GOAL.MD. Physician-supervised telehealth. More at goal.md/answers.